| Chemotherapy-induced nausea and vomiting
Akynzeo vs Varubi
Side-by-side clinical, coverage, and cost comparison for chemotherapy-induced nausea and vomiting.Deep comparison between: Akynzeo vs Varubi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVarubi has a higher rate of injection site reactions vs Akynzeo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Varubi but not Akynzeo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Akynzeo
Varubi
At A Glance
Oral or IV infusion
Once per chemotherapy cycle
NK-1 / 5-HT3 receptor antagonist
Oral
Once per chemotherapy cycle
NK1 receptor antagonist
Indications
- Chemotherapy-induced nausea and vomiting
- Chemotherapy-induced nausea and vomiting
Dosing
Chemotherapy-induced nausea and vomiting 1 capsule orally 1 hour before, or 1 vial IV over 30 minutes starting 30 minutes before, each chemotherapy cycle; administer with dexamethasone.
Chemotherapy-induced nausea and vomiting 180 mg as a single oral dose within 2 hours prior to initiation of chemotherapy, in combination with a 5-HT3 receptor antagonist and dexamethasone; administer at no less than 2-week intervals per chemotherapy cycle.
Contraindications
—
- Concomitant use with CYP2D6 substrates with a narrow therapeutic index such as thioridazine and pimozide, due to risk of QT prolongation and Torsades de Pointes
- Pediatric patients less than 2 years of age due to risk of irreversible impairment of sexual development and fertility
Adverse Reactions
Most common (>=3%) Headache, asthenia, fatigue, dyspepsia, constipation, erythema
Serious Hypersensitivity reactions, serotonin syndrome
Most common (>=3%) Neutropenia, decreased appetite, dizziness, hiccups, dyspepsia, urinary tract infection, stomatitis, abdominal pain, anemia
Pharmacology
Netupitant is a selective NK-1 receptor antagonist that blocks substance P-mediated delayed emesis; palonosetron is a 5-HT3 receptor antagonist that inhibits serotonin-mediated acute emesis at vagal afferents and the chemoreceptor trigger zone.
Rolapitant is a selective and competitive antagonist of human substance P/NK1 receptors; it does not have significant affinity for NK2 or NK3 receptors or other receptors, transporters, enzymes, or ion channels, and is active in animal models of chemotherapy-induced emesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Akynzeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Varubi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (2/12) · Qty limit (9/12)
UnitedHealthcare
Akynzeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Varubi
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Akynzeo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Varubi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Akynzeo.
No savings programs available for Varubi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AkynzeoView full Akynzeo profile
VarubiView full Varubi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.